Chronic lymphocytic leukaemia: Current management;Prise en charge actuelle de la leucémie lymphoïde chronique

Revue de Medecine Interne

Volumn 29, Issue 5, 2008, Pages 424-435

  Aurran Schleinitz, T ^a   Arnoulet, C ^a   Ivanov, V ^a   Coso, D ^a   Rey, J ^a   Schiano, J M ^a   Stoppa, A M ^a   Bouabdallah, R ^a   Gastaut, J A ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Fludarabine; Prognostic factors; Rituximab

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOLOGIC AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; PROTEIN KINASE ZAP 70; RITUXIMAB; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; DISEASE COURSE; HISTORY OF MEDICINE; HUMAN; IMMUNOTHERAPY; PROGNOSIS; PROTEIN EXPRESSION; SHORT SURVEY; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 43049088388     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.10.414     Document Type: Short Survey

References (83)

1. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
2. Binet J.L., Caligaris-Cappio F., Catovsky D., Cheson B., Davis T., Dighiero G., et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107 (2006) 859-861
3. Chiorazzi N., Rai K.R., and Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 352 (2005) 804-815
4. Schroeder Jr. H.W., and Dighiero G. The pathogenesis of chronic lymphocytic leukemia: Analysis of the antibody repertoire. Immunol Today 15 (1994) 288-294
5. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig v gene mutation status and cd38 expression as novel prognostic indicators in chronic lymphocytic leukaemia. Blood 94 (1999) 1840-1847
6. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., and Stevenson F.K. Unmutated ig v(h) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (1999) 1848-1854
7. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of b cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory b cells. J Exp Med 194 (2001) 1625-1638
8. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in b cell chronic lymphocytic leukemia. J Exp Med 194 (2001) 1639-1647
9. Damle R.N., Ghiotto F., Valetto A., Albesiano E., Fais F., Yan X.J., et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced b lymphocytes. Blood 99 (2002) 4087-4093
10. Messmer B.T., Albesiano E., Efremov D.G., Ghiotto F., Allen S.L., Kolitz J., et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 200 (2004) 519-525
11. Herve M., Xu K., Ng Y.S., Wardemann H., Albesiano E., Messmer B.T., et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive b cell precursors despite expressing different antibody reactivity. J Clin Invest 115 (2005) 1636-1643
12. Cerutti A., Zan H., Kim E.C., Shah S., Schattner E.J., Schaffer A., et al. Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia b cells. J Immunol 169 (2002) 6594-6603
13. Marti G.E., Rawstron A.C., Ghia P., Hillmen P., Houlston R.S., Kay N., et al. Diagnostic criteria for monoclonal b-cell lymphocytosis. Br J Haematol 130 (2005) 325-332
14. Aurran-Schleinitz T., Telford W., Perfetto S., Caporaso N., Wilson W., Stetler-Stevenson M.A., et al. Identification of a new monoclonal b-cell subset in unaffected first-degree relatives in familial chronic lymphocytic leukemia. Leukemia 19 (2005) 2339-2341
15. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1981) 198-206
16. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., and Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219-234
17. Muntanola A., Bosch F., Arguis P., Arellano-Rodrigo E., Ayuso C., Gine E., et al. Abdominal computed tomography predicts progression in patients with rai stage 0 chronic lymphocytic leukemia. J Clin Oncol 25 (2007) 1576-1580
18. Rozman C., Montserrat E., Rodriguez-Fernandez J.M., Ayats R., Vallespi T., Parody R., et al. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 64 (1984) 642-648
19. Montserrat E., Sanchez-Bisono J., Vinolas N., and Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br J Haematol 62 (1986) 567-575
20. Sarfati M., Chevret S., Chastang C., Biron G., Stryckmans P., Delespesse G., et al. Prognostic importance of serum soluble cd23 level in chronic lymphocytic leukemia. Blood 88 (1996) 4259-4264
21. Keating M.J. Chronic lymphocytic leukemia. Semin Oncol 26 (1999) 107-114
22. Hallek M., Langenmayer I., Nerl C., Knauf W., Dietzfelbinger H., Adorf D., et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93 (1999) 1732-1737
23. Saka B., Aktan M., Sami U., Oner D., Sanem O., and Dincol G. Prognostic importance of soluble cd23 in b-cell chronic lymphocytic leukemia. Clin Lab Haematol 28 (2006) 30-35
24. Hallek M., Wanders L., Ostwald M., Busch R., Senekowitsch R., Stern S., et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22 (1996) 439-447
25. Di Raimondo F., Giustolisi R., Lerner S., Cacciola E., O'Brien S., Kantarjian H., et al. Retrospective study of the prognostic role of serum thymidine kinase level in cll patients with active disease treated with fludarabine. Ann Oncol 12 (2001) 621-625
26. Montserrat E., Vinolas N., Reverter J.C., and Rozman C. Natural history of chronic lymphocytic leukemia: On the progression and progression and prognosis of early clinical stages. Nouv Rev Fr Hematol 30 (1988) 359-361
27. Wierda W.G., O'Brien S., Wang X., Faderl S., Ferrajoli A., Do K.A., et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109 (2007) 4679-4685
28. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukaemia. N Engl J Med 343 (2000) 1910-1916
29. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., et al. A microrna signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353 (2005) 1793-1801
30. Krober A., Seiler T., Benner A., Bullinger L., Bruckle E., Lichter P., et al. V(h) mutation status, cd38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100 (2002) 1410-1416
31. Lin K., Sherrington P.D., Dennis M., Matrai Z., Cawley J.C., and Pettitt A.R. Relationship between p53 dysfunction, cd38 expression, and igv(h) mutation in chronic lymphocytic leukemia. Blood 100 (2002) 1404-1409
32. Ghia P., Guida G., Stella S., Gottardi D., Geuna M., Strola G., et al. The pattern of cd38 expression defines a distinct subset of chronic lymphocytic leukemia (cll) patients at risk of disease progression. Blood 101 (2003) 1262-1269
33. Chang C.C., and Cleveland R.P. Conversion of cd38 and/or myeloid-associated marker expression status during the course of b-cll: Association with a change to an aggressive clinical course. Blood 100 (2002) 1106
34. Hamblin T.J., Orchard J.A., Ibbotson R.E., Davis Z., Thomas P.W., Stevenson F.K., et al. Cd38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but cd38 expression may vary during the course of the disease. Blood 99 (2002) 1023-1029
35. Ibrahim S., Keating M., Do K.A., O'Brien S., Huh Y.O., Jilani I., et al. Cd38 expression as an important prognostic factor in b-cell chronic lymphocytic leukemia. Blood 98 (2001) 181-186
36. Ghia P., Guida G., Scielzo C., Geuna M., and Caligaris-Cappio F. Cd38 modifications in chronic lymphocytic leukemia: Are they relevant?. Leukemia 18 (2004) 1733-1735
37. Chevallier P., Penther D., Avet-Loiseau H., Robillard N., Ifrah N., Mahe B., et al. Cd38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 116 (2002) 142-150
38. Thunberg U., Johnson A., Roos G., Thorn I., Tobin G., Sallstrom J., et al. Cd38 expression is a poor predictor for vh gene mutational status and prognosis in chronic lymphocytic leukaemia. Blood 97 (2001) 1892-1894
39. Oscier D.G., Gardiner A.C., Mould S.J., Glide S., Davis Z.A., Ibbotson R.E., et al. Multivariate analysis of prognostic factors in cll: Clinical stage, igvh gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100 (2002) 1177-1184
40. Wiestner A., Rosenwald A., Barry T.S., Wright G., Davis R.E., Henrickson S.E., et al. Zap-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101 (2003) 4944-4951
41. Chen L., Apgar J., Huynh L., Dicker F., Giago-McGahan T., Rassenti L., et al. Zap-70 directly enhances igm signaling in chronic lymphocytic leukemia. Blood 105 (2005) 2036-2041
42. Richardson S.J., Matthews C., Catherwood M.A., Alexander H.D., Carey B.S., Farrugia J., et al. Zap-70 expression is associated with enhanced ability to respond to migratory and survival signals in b-cell chronic lymphocytic leukemia (b-cll). Blood 107 (2006) 3584-3592
43. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. Zap-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
44. Orchard J.A., Ibbotson R.E., Davis Z., Wiestner A., Rosenwald A., Thomas P.W., et al. Zap-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363 (2004) 105-111
45. Rassenti L.Z., Huynh L., Toy T.L., Chen L., Keating M.J., Gribben J.G., et al. Zap-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
46. Zanotti R., Ambrosetti A., Lestani M., Ghia P., Pattaro C., Remo A., et al. Zap-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase cll patients, is a strong adverse prognostic factor. Leukemia 21 (2007) 102-109
47. Del Principe M.I., Del Poeta G., Buccisano F., Maurillo L., Venditti A., Zucchetto A., et al. Clinical significance of zap-70 protein expression in b-cell chronic lymphocytic leukemia. Blood 108 (2006) 853-861
48. Kay N.E., O'Brien S.M., Pettitt A.R., and Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 14 (2007) 14
49. Krober A., Bloehdorn J., Hafner S., Buhler A., Seiler T., Kienle D., et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and v3-21 usage characterize discordance of zap-70 and vh mutation status in chronic lymphocytic leukemia. J Clin Oncol 24 (2006) 969-975
50. Grever M.R., Lucas D.M., Dewald G.W., Neuberg D.S., Reed J.C., Kitada S., et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the us intergroup phase iii trial e2997. J Clin Oncol 25 (2007) 799-804
51. CII Trialists Collaboration Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 91 (1999) 861-868
52. Leporrier M., Chevret S., Cazin B., Boudjerra N., Feugier P., Desablens B., et al. Randomized comparison of fludarabine, cap, and chop in 938 previously untreated stage b and c chronic lymphocytic leukemia patients. Blood 98 (2001) 2319-2325
53. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemia. N Engl J Med 343 (2000) 1750-1757
54. Brugiatelli M., Bandini G., Barosi G., Lauria F., Liso V., Marchetti M., et al. Management of chronic lymphocytic leukemia: Practice guidelines from the italian society of hematology, the italian society of experimental hematology and the italian group for bone marrow transplantation. Haematologica 91 (2006) 1662-1673
55. Catovsky D., Richards S., Matutes E., Oscier D., Dyer M.J., Bezares R.F., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the lrf cll4 trial): A randomised controlled trial. Lancet 370 (2007) 230-239
56. Yamauchi T., Nowak B.J., Keating M.J., and Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7 (2001) 3580-3589
57. O'Brien S.M., Kantarjian H.M., Cortes J., Beran M., Koller C.A., Giles F.J., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19 (2001) 1414-1420
58. Eichhorst B.F., Busch R., Hopfinger G., Pasold R., Hensel M., Steinbrecher C., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 (2006) 885-891
59. Flinn I.W., Neuberg D.S., Grever M.R., Dewald G.W., Bennett J.M., Paietta E.M., et al. Phase iii trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: Us intergroup trial e2997. J Clin Oncol 25 (2007) 793-798
60. Esteve J., Villamor N., Colomer D., Cervantes F., Campo E., Carreras E., et al. Stem cell transplantation for chronic lymphocytic leukemia: Different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 15 (2001) 445-451
61. Milligan D.W., Fernandes S., Dasgupta R., Davies F.E., Matutes E., Fegan C.D., et al. Results of the mrc pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105 (2005) 397-404
62. Dreger P., Stilgenbauer S., Benner A., Ritgen M., Krober A., Kneba M., et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: A risk-matched analysis based on the vh gene mutational status. Blood 103 (2004) 2850-2858
63. Huhn D., von Schilling C., Wilhelm M., Ho A.D., Hallek M., Kuse R., et al. Rituximab therapy of patients with b-cell chronic lymphocytic leukemia. Blood 98 (2001) 1326-1331
64. O'Brien S.M., Kantarjian H., Thomas D.A., Giles F.J., Freireich E.J., Cortes J., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 (2001) 2165-2170
65. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Park K., et al. Rituximab using a thrice weekly dosing schedule in b-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001) 2153-2164
66. Hainsworth J.D., Litchy S., Barton J.H., Houston G.A., Hermann R.C., Bradof J.E., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase ii trial of the minnie pearl cancer research network. J Clin Oncol 21 (2003) 1746-1751
67. Byrd J.C., Rai K., Peterson B.L., Appelbaum F.R., Morrison V.A., Kolitz J.E., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of calgb 9712 and calgb 9011. Blood 105 (2005) 49-53
68. Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M., Lucas D., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with b-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
69. Keating M.J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4079-4088
70. Dohner H., Fischer K., Bentz M., Hansen K., Benner A., Cabot G., et al. P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic b-cell leukemias. Blood 85 (1995) 1580-1589
71. Keating M.J., Flinn I., Jain V., Binet J.L., Hillmen P., Byrd J., et al. Therapeutic role of alemtuzumab (campath-1h) in patients who have failed fludarabine: Results of a large international study. Blood 99 (2002) 3554-3561
72. Pettitt A.R., Matutes E., and Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 20 (2006) 1441-1445
73. Lundin J., Kimby E., Bjorkholm M., Broliden P.A., Celsing F., Hjalmar V., et al. Phase ii trial of subcutaneous anti-cd52 monoclonal antibody alemtuzumab (campath-1h) as first-line treatment for patients with b-cell chronic lymphocytic leukemia (b-cll). Blood 100 (2002) 768-773
74. Faderl S., Coutre S., Byrd J.C., Dearden C., Denes A., Dyer M.J., et al. The evolving role of alemtuzumab in management of patients with cll. Leukemia 19 (2005) 2147-2152
75. Keating M., Coutre S., Rai K., Osterborg A., Faderl S., Kennedy B., et al. Management guidelines for use of alemtuzumab in b-cell chronic lymphocytic leukemia. Clin Lymphoma 4 (2004) 220-227
76. Montillo M., Tedeschi A., Miqueleiz S., Veronese S., Cairoli R., Intropido L., et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 24 (2006) 2337-2342
77. O'Brien S.M., Kantarjian H.M., Thomas D.A., Cortes J., Giles F.J., Wierda W.G., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98 (2003) 2657-2663
78. Kennedy B., Rawstron A., Carter C., Ryan M., Speed K., Lucas G., et al. Campath-1h and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99 (2002) 2245-2247
79. Faderl S., Thomas D.A., O'Brien S., Garcia-Manero G., Kantarjian H.M., Giles F.J., et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101 (2003) 3413-3415
80. Dreger P., Corradini P., Kimby E., Michallet M., Milligan D., Schetelig J., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The ebmt transplant consensus. Leukemia 21 (2007) 12-17
81. Paneesha S., and Milligan D.W. Stem cell transplantation for chronic lymphocytic leukaemia. Br J Haematol 128 (2005) 145-152
82. Rawstron A.C., Kennedy B., Evans P.A., Davies F.E., Richards S.J., Haynes A.P., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98 (2001) 29-35
83. Rawstron A.C., Villamor N., Ritgen M., Bottcher S., Ghia P., Zehnder J.L., et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21 (2007) 956-964